An In Silico Study of Resveratrol Derivatives as Dual Inhibitors of Cyclooxygenase‐2 (COX‐2) and 5‐Lipoxygenase (5‐LOX) in Cancer Therapy
Biotechnology and Applied Biochemistry · 2026
DOI: 10.1002/bab.70150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2026. Verfasst von Sayali Doiphode und 3 weiteren Autor:innen. Beteiligte Einrichtung: Bioinformatics Centre, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Tathawade, Pune, India. Hauptthemen laut MEDLINE: Resveratrol, Lipoxygenase Inhibitors, Arachidonate 5-Lipoxygenase, Cyclooxygenase 2 Inhibitors. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: DST-SERB, Govt. of India, Bioinformatics Centre, Savitribai Phule Pune University.
Abstract (Originalsprache)
Chronic inflammation plays a crucial role in cancer initiation, progression, and metastasis, with cyclooxygenase‐2 (COX‐2) and 5‐lipoxygenase (5‐LOX) often co‐expressed and upregulated in tumor‐associated inflammatory microenvironments. Resveratrol, a naturally occurring polyphenolic compound, has been reported to exert anticancer effects by influencing processes such as angiogenesis, apoptosis, cell proliferation, and inflammatory signaling. In this study, resveratrol derivatives were retrieved from the PubChem database using a similarity‐based approach and evaluated as potential dual inhibitors of COX‐2 and 5‐LOX through molecular docking and 100 ns molecular dynamics (MD) simulations. The top four derivatives, FRV126, FRV169, FRV129, and FRV217, showed better docking scores than resveratrol for both targets. Analysis of MD trajectories, including root mean square deviation (RMSD), root mean square fluctuation (RMSF), hydrogen‐bond profiles, and compactness (radius of gyration), indicated that these complexes remained stable throughout the simulation period. Molecular mechanics/generalized Born surface area (MM/GBSA) analysis supported strong protein–ligand interactions, whereas in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) evaluation indicated desirable pharmacokinetic and safety profiles. These findings highlight the identified resveratrol derivatives as promising dual COX‐2/5‐LOX inhibitors for further development in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioinformatics Centre, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Tathawade, Pune, India.
- Bioinformatics Centre, Savitribai Phule Pune University, Pune, India.
- MIT School of Bioengineering Sciences & Research, MIT Art, Design and Technology University, Pune, India.
Förderung
- DST-SERB, Govt. of India
- Bioinformatics Centre, Savitribai Phule Pune University
Zitieren
APA
Doiphode, S., Ghosh, P., Swamy, K. V., & Nagar, S. (2026). An In Silico Study of Resveratrol Derivatives as Dual Inhibitors of Cyclooxygenase‐2 (COX‐2) and 5‐Lipoxygenase (5‐LOX) in Cancer Therapy. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.70150
Vancouver
Doiphode S, Ghosh P, Swamy KV, Nagar S. An In Silico Study of Resveratrol Derivatives as Dual Inhibitors of Cyclooxygenase‐2 (COX‐2) and 5‐Lipoxygenase (5‐LOX) in Cancer Therapy. Biotechnology and Applied Biochemistry. 2026. doi:10.1002/bab.70150
BibTeX
@article{Doiphode2026,
author = {Doiphode, Sayali and Ghosh, Payel and Swamy, K Venkateswara and Nagar, Shuchi},
title = {An In Silico Study of Resveratrol Derivatives as Dual Inhibitors of Cyclooxygenase‐2 (COX‐2) and 5‐Lipoxygenase (5‐LOX) in Cancer Therapy},
journal = {Biotechnology and Applied Biochemistry},
year = {2026},
doi = {10.1002/bab.70150}
}
EUVIMED